Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00020631 · ClinicalTrials.gov registry record · NA
Pirfenidone in Treating Patients With Fibrosis Caused by Radiation Therapy for Cancer
A NA study of Radiation Fibrosis, sponsored by National Cancer Institute (NCI).
- Completed
- Registry status
- NA
- Development phase
- 1
- Study location
NCT00020631 is a NA study of Radiation Fibrosis that has completed, run by National Cancer Institute (NCI). The trial reports 1 study location across 1 state.
The verdict
NCT00020631, a NA study of Radiation Fibrosis, has completed, sponsored by National Cancer Institute (NCI).
- COMPLETED
- Registry status
- NA
- Development phase
- 1
- Study location
Study Summary
RATIONALE: Pirfenidone may prevent or lessen fibrosis caused by radiation therapy. PURPOSE: Pilot trial to study the effectiveness of pirfenidone in preventing or lessening fibrosis in patients who have undergone radiation therapy for cancer.
Conditions Studied
Interventions
- DRUG pirfenidone
Study Locations (1)
Maryland
- Warren Grant Magnuson Clinical Center - NCI Clinical Studies Support - Bethesda
Trial Details
| Field | Value |
|---|---|
| Start Date | 2001-10 |
| Est. Completion | 2007-10 |
| Phase | NA |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00020631
The ClinicalTrials.gov registry entry for NCT00020631 describes a study currently listed as completed, categorized as NA. An enrollment target was not published in the registry record, which is common for early-stage or observational entries. The listed sponsor is National Cancer Institute (NCI), which has 3,257 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Radiation Fibrosis appearing as the primary indexed condition, and to 1 intervention - of which pirfenidone is the first listed.
NCT00020631 reports 1 study location spanning 1 distinct geographic area - top geographies include Maryland.
Frequently Asked Questions
What is clinical trial NCT00020631 about?
NCT00020631 is a clinical study titled "Pirfenidone in Treating Patients With Fibrosis Caused by Radiation Therapy for Cancer". RATIONALE: Pirfenidone may prevent or lessen fibrosis caused by radiation therapy. PURPOSE: Pilot trial to study the effectiveness of pirfenidone in preventing or lessening fibrosis in patients who have undergone radiation therapy for cancer.
What is the current status of trial NCT00020631?
This trial is currently completed. It is a NA study. The study started on 2001-10. Estimated completion is 2007-10.
What conditions does trial NCT00020631 study?
This clinical trial studies the following conditions: Radiation Fibrosis.
What interventions are being tested in trial NCT00020631?
The interventions under investigation include: pirfenidone (DRUG).
Who is sponsoring clinical trial NCT00020631?
This trial is sponsored by National Cancer Institute (NCI), which has 3,257 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT00020631 being conducted?
This trial has 1 study location across Maryland. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Radiation Fibrosis
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.